AbbVie Completes Acquisition of Cerevel Therapeutics [Yahoo! Finance]
Cerevel Therapeutics Holdings, Inc. (CERE)
Company Research
Source: Yahoo! Finance
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of ; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of NORTH CHICAGO, Ill. Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the acquisition, Cerevel is now part of AbbVie. "AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond," said Robert A. Michael , chief executive officer, AbbVie. "Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living wi
Show less
Read more
Impact Snapshot
Event Time:
CERE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CERE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CERE alerts
High impacting Cerevel Therapeutics Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CERE
News
- AbbVie acquires Cerevel Therapeutics for $8.7bn [Yahoo! Finance]Yahoo! Finance
- The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To EngageAccesswire
- The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of ItAccesswire
- The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To ParticipateAccesswire
CERE
Earnings
- 5/8/24 - Miss
CERE
Sec Filings
- 8/1/24 - Form 25-NSE
- 8/1/24 - Form S-8
- 8/1/24 - Form S-8
- CERE's page on the SEC website